Ventyx Biosciences IncNASDAQ:VTYX
- LAST PRICE4.5000
- TODAY'S CHANGE (%)0.0600 (1.3514%)
- Bid / Lots4.4900/ 2
- Ask / Lots4.5100/ 3
- Open / Previous Close4.5000 / 4.4400
- Day Range
- 52 Week Range
- Volume173,625
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VTYX |
|---|---|---|
| 09:32 ET | 5675 | 4.4001 |
| 09:34 ET | 100 | 4.47 |
| 09:36 ET | 2364 | 4.43 |
| 09:38 ET | 1200 | 4.4284 |
| 09:41 ET | 400 | 4.44 |
| 09:43 ET | 500 | 4.4584 |
| 09:48 ET | 994 | 4.5 |
| 09:54 ET | 621 | 4.5016 |
| 09:56 ET | 1761 | 4.48 |
| 09:57 ET | 922 | 4.43 |
| 09:59 ET | 1390 | 4.4632 |
| 10:01 ET | 248 | 4.47 |
| 10:03 ET | 1808 | 4.49 |
| 10:06 ET | 1500 | 4.4899 |
| 10:08 ET | 900 | 4.49 |
| 10:10 ET | 1535 | 4.5084 |
| 10:12 ET | 625 | 4.51 |
| 10:14 ET | 100 | 4.51 |
| 10:15 ET | 14664 | 4.485 |
| 10:17 ET | 300 | 4.49 |
| 10:19 ET | 100 | 4.49 |
| 10:21 ET | 2335 | 4.49 |
| 10:24 ET | 1200 | 4.5 |
| 10:26 ET | 9913 | 4.485 |
| 10:28 ET | 2534 | 4.49 |
| 10:30 ET | 400 | 4.49 |
| 10:32 ET | 2154 | 4.501 |
| 10:33 ET | 300 | 4.4908 |
| 10:35 ET | 1737 | 4.495 |
| 10:37 ET | 2150 | 4.49 |
| 10:39 ET | 300 | 4.49 |
| 10:44 ET | 1129 | 4.4811 |
| 10:46 ET | 100 | 4.48 |
| 10:48 ET | 900 | 4.49 |
| 10:50 ET | 2155 | 4.53 |
| 10:51 ET | 6289 | 4.57 |
| 10:53 ET | 8808 | 4.58 |
| 10:55 ET | 7027 | 4.585 |
| 10:57 ET | 576 | 4.6 |
| 11:00 ET | 12336 | 4.61 |
| 11:04 ET | 100 | 4.62 |
| 11:06 ET | 1163 | 4.61 |
| 11:08 ET | 200 | 4.62 |
| 11:09 ET | 2900 | 4.6299 |
| 11:11 ET | 200 | 4.61 |
| 11:15 ET | 916 | 4.63 |
| 11:18 ET | 100 | 4.63 |
| 11:20 ET | 1863 | 4.62 |
| 11:22 ET | 201 | 4.6283 |
| 11:26 ET | 600 | 4.61 |
| 11:27 ET | 1000 | 4.61 |
| 11:29 ET | 580 | 4.59 |
| 11:31 ET | 408 | 4.58 |
| 11:33 ET | 1200 | 4.58 |
| 11:40 ET | 300 | 4.58 |
| 11:42 ET | 2576 | 4.58 |
| 11:44 ET | 3616 | 4.6 |
| 11:47 ET | 200 | 4.6 |
| 11:51 ET | 1100 | 4.6 |
| 11:54 ET | 359 | 4.59 |
| 11:56 ET | 2150 | 4.605 |
| 11:58 ET | 4554 | 4.57 |
| 12:05 ET | 100 | 4.54 |
| 12:16 ET | 600 | 4.55 |
| 12:18 ET | 550 | 4.56 |
| 12:20 ET | 300 | 4.56 |
| 12:21 ET | 200 | 4.56 |
| 12:25 ET | 1593 | 4.54 |
| 12:27 ET | 1500 | 4.53 |
| 12:36 ET | 1374 | 4.53 |
| 12:38 ET | 7741 | 4.5 |
| 12:43 ET | 400 | 4.505 |
| 12:45 ET | 820 | 4.51 |
| 12:48 ET | 1075 | 4.5 |
| 12:50 ET | 1400 | 4.5 |
| 12:54 ET | 1200 | 4.5 |
May 2, 2024
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024, from 4:05PM ET on Thursday May 02, 2024 by Dow Jones
4:05PM ET on Thursday May 02, 2024 by Dow Jones
May 1, 2024
Lifshitz Law PLLC Announces Investigations of Snowflake Inc. (NYSE:SNOW), The Children's Place, Inc. (NASDAQ:PLCE), Nextdoor Holdings, Inc. (NYSE:KIND), and Ventyx Biosciences, Inc. (NASDAQ:VTYX), from 11:26PM ET on Wednesday May 01, 2024 by Dow Jones
11:26PM ET on Wednesday May 01, 2024 by Dow Jones
Apr 30, 2024
April 30, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTYX, from 2:16PM ET on Tuesday Apr 30, 2024 by Dow Jones
2:16PM ET on Tuesday Apr 30, 2024 by Dow JonesVTYX DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX, from 1:31PM ET on Tuesday Apr 30, 2024 by Dow Jones
1:31PM ET on Tuesday Apr 30, 2024 by Dow JonesVTYX DEADLINE TODAY: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX, from 1:04PM ET on Tuesday Apr 30, 2024 by Dow Jones
1:04PM ET on Tuesday Apr 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ventyx Biosciences Inc | 313.0M | -1.4x | --- |
Fibrobiologics Inc | 312.8M | -9.8x | --- |
Anavex Life Sciences Corp | 314.0M | -7.2x | --- |
Candel Therapeutics Inc | 317.8M | -8.1x | --- |
Q32 Bio Inc | 313.5M | -0.7x | --- |
Invivyd Inc | 301.6M | -1.4x | --- |
Company Information
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Contact Information
- Headquarters
- 12790 El Camino Real, Suite 200SAN DIEGO, CA, United States 92130
- Phone
- 858-945-2393
- Fax
- 302-655-5049
Executives
- Executive Chairperson of the Board
- Sheila Gujrathi
- President, Chief Executive Officer, Founder, Director
- Raju Mohan
- Chief Financial Officer
- Martin Auster
- Chief Scientific Officer
- John Nuss
- Independent Director
- Onaiza Cadoret-manier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $313.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.29 |
Book Value | $4.12 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
